Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting No phase listed Observational

Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)

ClinicalTrials.gov ID: NCT03428646

Public ClinicalTrials.gov record NCT03428646. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 6:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective Observational Study of Patients Receiving DUPIXENT® for Atopic Dermatitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A long-term observational registry in patients with atopic dermatitis (AD) initiating treatment with DUPIXENT® (dupilumab)

Study identification

NCT ID
NCT03428646
Recruitment status
Active, not recruiting
Study type
Observational
Phase
Not listed
Lead sponsor
Regeneron Pharmaceuticals
Industry
Enrollment
858 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 6, 2018 (Actual)
Primary completion
Mar 30, 2027 (Estimated)
Completion
Jul 28, 2027 (Estimated)
Last update posted
Oct 9, 2026

2018 – 2027

United States locations

U.S. sites
93
U.S. states
28
U.S. cities
86
Facility City State ZIP Site status
Regeneron Investigational Site Birmingham Alabama 35205 —
Regeneron Investigational Site Gilbert Arizona 85234 —
Regeneron Investigational Site Fountain Valley California 92708 —
Regeneron Investigational Site Laguna Hills California 92653 —
Regeneron Investigational Site Loma Linda California 92354 —
Regeneron Investigational Site Los Angeles California 90025 —
Regeneron Investigational Site Los Angeles California 90067 —
Regeneron Investigational Site Manhattan Beach California 90266-2911 —
Regeneron Investigational Site Newport Beach California 92663 —
Regeneron Investigational Site Oceanside California 92056 —
Regeneron Investigational Site Redondo Beach California 90277 —
Regeneron Investigational Site Riverside California 92506-0174 —
Regeneron Investigational Site Roseville California 95661 —
Regeneron Investigational Site San Diego California 92123 —
Regeneron Investigational Site Santa Monica California 90404 —
Regeneron Investigational Site Thousand Oaks California 91320 —
Regeneron Investigational Site New Haven Connecticut 06519 —
Regeneron Investigational Site Coral Gables Florida 33146 —
Regeneron Investigational Site Margate Florida 33063 —
Regeneron Investigational Site West Palm Beach Florida 33406 —
Regeneron Investigational Site Atlanta Georgia 30342-1703 —
Regeneron Investigational Site Macon Georgia 31217 —
Regeneron Investigational Site Marietta Georgia 30060-1047 —
Regeneron Investigational Site Marietta Georgia 30152 —
Regeneron Investigational Site Sandy Springs Georgia 30328 —
Regeneron Investigational Site Champaign Illinois 61820 —
Regeneron Investigational Site Chicago Illinois 60654 —
Regeneron Investigational Site La Grange Park Illinois 60526 —
Regeneron Investigational Site Skokie Illinois 60077 —
Regeneron Investigational Site Springfield Illinois 62604 —
Regeneron Investigational Site Fort Wayne Indiana 46804 —
Regeneron Investigational Site Plainfield Indiana 46168 —
Regeneron Investigational Site Overland Park Kansas 66215 —
Regeneron Investigational Site Corbin Kentucky 40701 —
Regeneron Investigational Site Louisville Kentucky 40202 —
Regeneron Investigational Site Rockville Maryland 20850 —
Regeneron Investigational Site Towson Maryland 21204 —
Regeneron Investigational Site Upper Marlboro Maryland 20772 —
Regeneron Investigational Site White Marsh Maryland 21162 —
Regeneron Investigational Site Quincy Massachusetts 02169 —
Regeneron Investigational Site Ann Arbor Michigan 48103 —
Regeneron Investigational Site Bay City Michigan 48706 —
Regeneron Investigational Site Troy Michigan 48084 —
Regeneron Investigational Site Warren Michigan 48088 —
Regeneron Investigational Site Columbia Missouri 65212-0001 —
Regeneron Investigational Site Kirksville Missouri 63501 —
Regeneron Investigational Site St Louis Missouri 63110 —
Regeneron Investigational Site Lincoln Nebraska 68505 —
Regeneron Investigational Site Henderson Nevada 89052 —
Regeneron Investigational Site Las Vegas Nevada 89144 —
Regeneron Investigational Site Brick New Jersey 08724 —
Regeneron Investigational Site East Windsor New Jersey 08520 —
Regeneron Investigational Site Edison New Jersey 08820 —
Regeneron Investigational Site Piscataway New Jersey 08854 —
Regeneron Investigational Site Elmhurst New York 11373-4831 —
Regeneron Investigational Site Forest Hills New York 11374 —
Regeneron Investigational Site Garden City New York 11530 —
Regeneron Investigational Site Kew Gardens New York 11374 —
Regeneron Investigational Site Lake Success New York 11042 —
Regeneron Investigational Site Manhasset New York 11030 —
Regeneron Investigational Site Mineola New York 11501 —
Regeneron Investigational Site Mount Vernon New York 10552 —
Regeneron Investigational Site New York New York 10012-1354 —
Regeneron Investigational Site New York New York 10016 —
Regeneron Investigational Site New York New York 10029 —
Regeneron Investigational Site New York New York 10075 —
Regeneron Investigational Site The Bronx New York 10467-2401 —
Regeneron Investigational Site Troy New York 12180 —
Regeneron Investigational Site Concord North Carolina 28025 —
Regeneron Investigational Site Akron Ohio 44333 —
Regeneron Investigational Site Athens Ohio 45701 —
Regeneron Investigational Site Bexley Ohio 43209 —
Regeneron Investigational Site Marion Ohio 43302 —
Regeneron Investigational Site Mason Ohio 45040 —
Regeneron Investigational Site Tulsa Oklahoma 74136 —
Regeneron Investigational Site Portland Oregon 97239 —
Regeneron Investigational Site Blue Bell Pennsylvania 19422 —
Regeneron Investigational Site Philadelphia Pennsylvania 19107 —
Regeneron Investigational Site Philadelphia Pennsylvania 19140 —
Regeneron Investigational Site Sellersville Pennsylvania 18960 —
Regeneron Investigational Site Yardley Pennsylvania 19067 —
Regeneron Investigational Site Charleston South Carolina 29425 —
Regeneron Investigational Site North Charleston South Carolina 29420-4211 —
Regeneron Investigational Site Bellaire Texas 77401 —
Regeneron Investigational Site Dallas Texas 75231 —
Regeneron Investigational Site Grapevine Texas 76051 —
Regeneron Investigational Site San Antonio Texas 78205 —
Regeneron Investigational Site Sugar Land Texas 77478 —
Regeneron Investigational Site Sugar Land Texas 77479 —
Regeneron Investigational Site Arlington Virginia 22204 —
Regeneron Investigational Site Norfolk Virginia 23502 —
Regeneron Investigational Site Bellevue Washington 98004 —
Regeneron Investigational Site Milwaukee Wisconsin 53226 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03428646, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 9, 2026 · Synced Oct 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03428646 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →